Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 11 studies | 25% ± 10% | |
fibroblast | 10 studies | 26% ± 13% | |
microglial cell | 6 studies | 25% ± 6% | |
oligodendrocyte | 6 studies | 25% ± 6% | |
macrophage | 6 studies | 30% ± 8% | |
epithelial cell | 5 studies | 24% ± 10% | |
astrocyte | 5 studies | 29% ± 9% | |
type I pneumocyte | 5 studies | 20% ± 6% | |
interneuron | 5 studies | 32% ± 21% | |
adipocyte | 4 studies | 23% ± 4% | |
GABAergic neuron | 4 studies | 45% ± 14% | |
glutamatergic neuron | 4 studies | 50% ± 18% | |
oligodendrocyte precursor cell | 4 studies | 30% ± 9% | |
endothelial cell of lymphatic vessel | 4 studies | 20% ± 6% | |
smooth muscle cell | 4 studies | 17% ± 2% | |
classical monocyte | 3 studies | 19% ± 1% | |
myeloid cell | 3 studies | 18% ± 1% | |
retinal rod cell | 3 studies | 23% ± 5% | |
hepatocyte | 3 studies | 32% ± 14% | |
pericyte | 3 studies | 25% ± 11% | |
goblet cell | 3 studies | 29% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 4170.84 | 1445 / 1445 | 100% | 30.70 | 183 / 183 |
lung | 100% | 5617.28 | 578 / 578 | 100% | 35.15 | 1155 / 1155 |
uterus | 100% | 6858.18 | 170 / 170 | 100% | 32.39 | 459 / 459 |
breast | 100% | 5766.08 | 459 / 459 | 100% | 45.97 | 1117 / 1118 |
intestine | 100% | 4353.61 | 966 / 966 | 100% | 23.92 | 526 / 527 |
prostate | 100% | 4126.29 | 245 / 245 | 100% | 25.36 | 501 / 502 |
skin | 100% | 5445.70 | 1809 / 1809 | 100% | 37.45 | 471 / 472 |
ovary | 100% | 7178.34 | 180 / 180 | 100% | 27.99 | 429 / 430 |
thymus | 100% | 4093.90 | 652 / 653 | 100% | 29.32 | 604 / 605 |
stomach | 100% | 3338.80 | 359 / 359 | 100% | 25.16 | 285 / 286 |
bladder | 100% | 5091.33 | 21 / 21 | 100% | 26.51 | 502 / 504 |
liver | 100% | 3035.15 | 226 / 226 | 100% | 32.45 | 404 / 406 |
pancreas | 100% | 2454.23 | 327 / 328 | 99% | 28.35 | 177 / 178 |
kidney | 100% | 2928.74 | 89 / 89 | 97% | 28.57 | 871 / 901 |
brain | 97% | 2076.04 | 2552 / 2642 | 100% | 22.65 | 705 / 705 |
adrenal gland | 100% | 4670.39 | 258 / 258 | 95% | 19.28 | 219 / 230 |
adipose | 100% | 5927.83 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 5587.76 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 26.09 | 29 / 29 |
spleen | 100% | 3839.77 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.95 | 1 / 1 |
muscle | 100% | 3819.99 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 3042.31 | 854 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 22.79 | 79 / 80 |
tonsil | 0% | 0 | 0 / 0 | 98% | 28.14 | 44 / 45 |
peripheral blood | 97% | 3001.74 | 904 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0046886 | Biological process | positive regulation of hormone biosynthetic process |
GO_0001892 | Biological process | embryonic placenta development |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0030522 | Biological process | intracellular receptor signaling pathway |
GO_0033235 | Biological process | positive regulation of protein sumoylation |
GO_0034599 | Biological process | cellular response to oxidative stress |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_0001938 | Biological process | positive regulation of endothelial cell proliferation |
GO_0030154 | Biological process | cell differentiation |
GO_0001666 | Biological process | response to hypoxia |
GO_0010575 | Biological process | positive regulation of vascular endothelial growth factor production |
GO_0045648 | Biological process | positive regulation of erythrocyte differentiation |
GO_0030949 | Biological process | positive regulation of vascular endothelial growth factor receptor signaling pathway |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005654 | Cellular component | nucleoplasm |
GO_0090575 | Cellular component | RNA polymerase II transcription regulator complex |
GO_0016604 | Cellular component | nuclear body |
GO_0034753 | Cellular component | nuclear aryl hydrocarbon receptor complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0034751 | Cellular component | aryl hydrocarbon receptor complex |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0017162 | Molecular function | aryl hydrocarbon receptor binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0000987 | Molecular function | cis-regulatory region sequence-specific DNA binding |
GO_0043565 | Molecular function | sequence-specific DNA binding |
GO_0004879 | Molecular function | nuclear receptor activity |
GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0046982 | Molecular function | protein heterodimerization activity |
GO_0005515 | Molecular function | protein binding |
Gene name | ARNT |
Protein name | Aryl hydrocarbon receptor nuclear translocator Aryl hydrocarbon receptor nuclear translocator (ARNT protein) (Class E basic helix-loop-helix protein 2) (bHLHe2) (Dioxin receptor, nuclear translocator) (Hypoxia-inducible factor 1-beta) (HIF-1-beta) (HIF1-beta) |
Synonyms | BHLHE2 |
Description | FUNCTION: Required for activity of the AHR. Upon ligand binding, AHR translocates into the nucleus, where it heterodimerizes with ARNT and induces transcription by binding to xenobiotic response elements (XRE). Not required for the ligand-binding subunit to translocate from the cytosol to the nucleus after ligand binding . The complex initiates transcription of genes involved in the regulation of a variety of biological processes, including angiogenesis, hematopoiesis, drug and lipid metabolism, cell motility and immune modulation (Probable). The heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters and functions as a transcriptional regulator of the adaptive response to hypoxia (By similarity). The heterodimer ARNT:AHR binds to core DNA sequence 5'-TGCGTG-3' within the dioxin response element (DRE) of target gene promoters and activates their transcription . . |
Accessions | ENST00000504358.1 P27540 F8T0U4 Q9UH46 ENST00000471844.6 I6L9E7 ENST00000505755.5 [P27540-2] O43392 F8T0U3 D6RDB3 A6NGV6 ENST00000515192.5 [P27540-3] ENST00000358595.10 [P27540-1] ENST00000354396.6 [P27540-4] |